Adial provides business update following favorable comments from us and eu regulatory meetings

Charlottesville, va., july 11, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) ("adial" or the "company"), a clinical-stage biopharmaceutical company focused on the development of ad04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of alcohol use disorder (“aud”), today provided a summary of feedback received following recent meetings with both us and eu regulators, as well as an update on the company's current clinical development plan based on guidance received.
ADIL Ratings Summary
ADIL Quant Ranking